Table 1.

Baseline Characteristics.

Age at first clot, median (range)	61.7 (19.5–88.9)
Gender
Female	136 (57.6%)
Male	100 (42.4%)
Solid Malignancy, n (%)	169 (71.6%)
Breast	30 (17.8%)
Colorectal	24 (14.3%)
Sarcoma	17 (10.1%)
Lung	13 (7.7%)
Ovarian	13 (7.7%)
Bladder	12 (7.1%)
Head and neck	9 (5.3%)
Other	51 (30.2%)
Solid stage, n (%)
Metastatic	98 (58.0%)
Localized	71 (42.0%)
Hematologic malignancy, n (%)	67 (28.4%)
Non-Hodgkins lymphoma	22 (32.8%)
Multiple myeloma	22 (32.8%)
Hodgkins lymphoma	6 (9.0%)
Chronic lymphocytic leukemia	6 (9.0%)
Acute myeloid leukemia	5 (7.5%)
Other	6 (9.0%)
Transplant (hematologic), n (%)	32 (47.8%)
Initial clot location
Deep vein thrombosis (DVT)	122 (51.7%)
Pulmonary embolism (PE)	69 (29.2%)
DVT and PE	22 (9.3%)
Inferior vena cava (IVC)	8 (3.4%)
Portal vein	4 (1.7%)
Intracardiac	3 (1.3%)
Intracranial Vein	3 (1.3%)
Gonadal	2 (0.8%)
Other	3 (1.3%)
Initial therapy, n (%)
Warfarin	132 (55.9%)
Enoxaparin	53 (22.5%)
Dalteparin	37 (15.7%)
Fondaparinux	14 (5.9%)